NASDAQ:CTCX Carmell (CTCX) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free CTCX Stock Alerts $2.63 +0.10 (+3.95%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$2.56▼$2.6550-Day Range$1.98▼$2.9052-Week Range$1.70▼$13.31Volume4,151 shsAverage Volume8,343 shsMarket Capitalization$54.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Carmell alerts: Email Address Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Carmell Stock (NASDAQ:CTCX)Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Read More CTCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTCX Stock News HeadlinesMay 23, 2024 | insidertrades.comRajiv Shukla Purchases 8,680 Shares of Carmell Co. (NASDAQ:CTCX) StockMay 25, 2024 | finance.yahoo.comCarmell Corporation (CTCX)May 16, 2024 | investorplace.comCTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023May 16, 2024 | investorplace.comCTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024April 11, 2024 | globenewswire.comCarmell Announces Successful Closing of $3.0 Million Private PlacementApril 4, 2024 | globenewswire.comCarmell Announces $3.0 Million Private PlacementMarch 27, 2024 | globenewswire.comCarmell Announces Successful Closing of Axolotl Biologix Sale TransactionMarch 22, 2024 | investing.comCarmell Corporation divests subsidiary to focus on skincareMarch 20, 2024 | globenewswire.comCarmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix SubsidiaryMarch 18, 2024 | globenewswire.comCarmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics FieldFebruary 28, 2024 | morningstar.comCarmell Corp Ordinary Shares - Class AFebruary 26, 2024 | msn.comWhy Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionFebruary 26, 2024 | globenewswire.comCarmell Announces Product Development Completed for G.L.E.E. Launch in March 2024January 6, 2024 | nasdaq.comCarmell Corporation Common Stock (CTCX)December 9, 2023 | morningstar.comCarmell Corp Ordinary Shares - Class A CTCXNovember 29, 2023 | msn.comCarmell CEO buys shares worth over $15.5k - filingNovember 16, 2023 | finance.yahoo.comCarmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of DirectorsSeptember 12, 2023 | finance.yahoo.comMoonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative MedicineSeptember 5, 2023 | finance.yahoo.comCarmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on AestheticsAugust 19, 2023 | seekingalpha.comCTCX Carmell Therapeutics CorporationAugust 9, 2023 | finance.yahoo.comCarmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand IdentityAugust 6, 2023 | ca.finance.yahoo.comCarmell Therapeutics Corporation (CTCX)August 1, 2023 | morningstar.comCarmell Therapeutics Corp Ordinary Shares - Class AJuly 28, 2023 | barrons.comCarmell Therapeutics Corp.July 28, 2023 | msn.comCarmell jumps on deal to merge with Axolotl BiologixSee More Headlines Receive CTCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carmell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/30/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTCX CUSIPN/A CIK1842939 Webwww.carmellrx.com Phone412-894-8248FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,440,000.00 Net MarginsN/A Pretax Margin-401.27% Return on Equity-171.27% Return on Assets-22.94% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-37.60Miscellaneous Outstanding Shares20,803,000Free FloatN/AMarket Cap$54.76 million OptionableNot Optionable Beta0.42 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Rajiv Sarman Shukla (Age 49)Executive Chairman & CEO Comp: $292.19kMr. Bryan J. Cassaday (Age 55)Chief Financial Officer Comp: $261.7kDr. Phil Campbell Ph.D.Founder and Chief Scientific OfficerDr. Lee Weiss Ph.D.FounderDr. James Burgess M.D.FounderKey CompetitorsAVITA MedicalNASDAQ:RCELTriSalus Life SciencesNASDAQ:TLSIOrchestra BioMedNASDAQ:OBIOAlpha Tau MedicalNASDAQ:DRTSClearPoint NeuroNASDAQ:CLPTView All CompetitorsInsiders & InstitutionsRajiv ShuklaBought 1,939 shares on 5/24/2024Total: $4,983.23 ($2.57/share)Rajiv ShuklaBought 4,051 shares on 5/22/2024Total: $9,762.91 ($2.41/share)Rajiv ShuklaBought 1,172 shares on 5/20/2024Total: $2,601.84 ($2.22/share)Hubbell Strickland Wealth Management LLCBought 12,548 shares on 4/18/2024Ownership: 0.065%Rajiv ShuklaBought 8,680 shares on 4/4/2024Total: $24,998.40 ($2.88/share)View All Insider TransactionsView All Institutional Transactions CTCX Stock Analysis - Frequently Asked Questions How have CTCX shares performed in 2024? Carmell's stock was trading at $3.81 at the beginning of 2024. Since then, CTCX shares have decreased by 30.9% and is now trading at $2.6321. View the best growth stocks for 2024 here. Are investors shorting Carmell? Carmell saw a increase in short interest in May. As of May 15th, there was short interest totaling 30,000 shares, an increase of 8.7% from the April 30th total of 27,600 shares. Based on an average daily volume of 10,500 shares, the short-interest ratio is currently 2.9 days. Approximately 0.2% of the company's shares are sold short. View Carmell's Short Interest. When is Carmell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our CTCX earnings forecast. Who are Carmell's major shareholders? Carmell's stock is owned by many different institutional and retail investors. Top institutional investors include Hubbell Strickland Wealth Management LLC (0.07%). Insiders that own company stock include Bryan J Cassaday, Gilles Spenlehauer, Rajiv Shukla, Randolph W Hubbell, Richard A Upton and Scott M Frisch. View institutional ownership trends. How do I buy shares of Carmell? Shares of CTCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTCX) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBiden Nomination CANCELED?The Freeport SocietyThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star[Urgent!] Generational Wealth GameplanCrypto 101 MediaGet out of dollars—get into America’s new money insteadStansberry ResearchThis unknown company solves the biggest issue with AIManward PressDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carmell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
